Neurocrine Biosciences, Inc. (NBIX) 10-Year Financial Performance & Capital Metrics

NBIX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCNS & Pain Management

AboutNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.Show more

Revenue $2.36B +24.8%
EBITDA $598M +119.5%
Net Income $341M +36.7%
EPS (Diluted) 3.29 +33.2%
Gross Margin 98.56% +0.7%
EBITDA Margin 25.37% +75.9%
Operating Margin 24.22% +82.2%
Net Margin 14.49% +9.5%
ROE 14.16% +11.7%
ROIC 16.39% +79.3%
Debt/Equity 0.18 -8.4%
Interest Coverage 4.51 -91.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 56.0%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 23.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 24.5%
✓Healthy 5Y average net margin of 17.0%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y24.48%

3Y27.61%

TTM19.61%

Profit (Net Income) CAGR

10Y-

5Y55.95%

3Y56.17%

TTM10.91%

EPS CAGR

10Y-

5Y53.19%

3Y52.92%

TTM12.06%

ROCE

10Y Avg-1.13%

5Y Avg12.98%

3Y Avg14.87%

Latest19.65%

Peer Comparison

CNS & Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NBIXNeurocrine Biosciences, Inc.	13.3B	133.35	40.53	24.81%	15.95%	14.25%	4.19%	0.18
SUPNSupernus Pharmaceuticals, Inc.	2.88B	50.26	38.08	8.94%	-2.8%	-1.82%	5.94%	0.03
PTPIPetros Pharmaceuticals, Inc.	338.98K	0.01	-0.00	-12.2%	-9.68%	-208.53%
QNTMQuantum BioPharma Ltd.	26.75M	6.96	-0.56			-379.78%		0.08
AYTUAytu BioPharma, Inc.	28.12M	2.76	-1.28	1.84%	-20.52%	-56.41%		1.21
AQSTAquestive Therapeutics, Inc.	407.49M	3.34	-6.55	13.8%	-158.95%
AVDLAvadel Pharmaceuticals plc	2.11B	21.48	-42.12	5.05%	-0.11%	-0.28%		0.02
RGCRegencell Bioscience Holdings Limited	14.86B	30.06	-3455.17			-67.02%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	19.77M	15M	161.63M	451.2M	788.1M	1.05B	1.13B	1.49B	1.89B	2.36B
Revenue Growth %	-	-0.24%	9.78%	1.79%	0.75%	0.33%	0.08%	0.31%	0.27%	0.25%
Cost of Goods Sold+	0	0	1.25M	4.9M	7.4M	10.1M	14.3M	23.2M	39.7M	34M
COGS % of Revenue	-	-	0.01%	0.01%	0.01%	0.01%	0.01%	0.02%	0.02%	0.01%
Gross Profit+	19.77M	15M	160.37M	446.3M	780.7M	1.04B	1.12B	1.47B	1.85B	2.32B
Gross Margin %	1%	1%	0.99%	0.99%	0.99%	0.99%	0.99%	0.98%	0.98%	0.99%
Gross Profit Growth %	2.37%	-0.24%	9.69%	1.78%	0.75%	0.33%	0.08%	0.31%	0.26%	0.26%
Operating Expenses+	113.97M	162.37M	291.73M	409.5M	708.4M	872.8M	1.02B	1.22B	1.6B	1.75B
OpEx % of Revenue	5.77%	10.82%	1.8%	0.91%	0.9%	0.83%	0.9%	0.82%	0.85%	0.74%
Selling, General & Admin	32.48M	68.08M	169.91M	248.93M	354.1M	433.3M	583.3M	752.7M	887.6M	1.01B
SG&A % of Revenue	1.64%	4.54%	1.05%	0.55%	0.45%	0.41%	0.51%	0.51%	0.47%	0.43%
Research & Development	81.49M	94.29M	91.83M	155.8M	200M	275M	328.1M	463.8M	565M	731.1M
R&D % of Revenue	4.12%	6.29%	0.57%	0.35%	0.25%	0.26%	0.29%	0.31%	0.3%	0.31%
Other Operating Expenses	0	0	30M	4.8M	154.3M	164.5M	105.3M	0	143.9M	12.5M
Operating Income+	-94.2M	-147.37M	-131.36M	36.8M	72.3M	163M	102.5M	249M	250.9M	570.5M
Operating Margin %	-4.77%	-9.82%	-0.81%	0.08%	0.09%	0.16%	0.09%	0.17%	0.13%	0.24%
Operating Income Growth %	-0.46%	-0.56%	0.11%	1.28%	0.96%	1.25%	-0.37%	1.43%	0.01%	1.27%
EBITDA+	-93.19M	-145.87M	-128.96M	40.82M	79.75M	171.6M	113.4M	264.6M	272.2M	597.6M
EBITDA Margin %	-4.71%	-9.72%	-0.8%	0.09%	0.1%	0.16%	0.1%	0.18%	0.14%	0.25%
EBITDA Growth %	-0.47%	-0.57%	0.12%	1.32%	0.95%	1.15%	-0.34%	1.33%	0.03%	1.2%
D&A (Non-Cash Add-back)	1.01M	1.5M	2.4M	4.02M	7.45M	8.6M	10.9M	15.6M	21.3M	27.1M
EBIT	-88.93M	-141.09M	-123.02M	52.3M	78.5M	139.5M	127.2M	249M	394.8M	612.6M
Net Interest Income+	1.93M	2.84M	-19.52M	-30.5M	-32M	-32.8M	-25.8M	4.1M	-4.6M	-35.6M
Interest Income	1.93M	2.84M	0	0	0	0	0	11.2M	0	91M
Interest Expense	0	0	19.52M	30.53M	32M	32.8M	25.8M	7.1M	4.6M	126.6M
Other Income/Expense	5.27M	6.28M	-11.18M	-15.05M	-25.8M	-56.3M	-1.1M	-35.1M	81.2M	-84.5M
Pretax Income+	-88.93M	-141.09M	-142.54M	21.84M	46.5M	106.7M	101.4M	213.9M	332.1M	486M
Pretax Margin %	-4.5%	-9.41%	-0.88%	0.05%	0.06%	0.1%	0.09%	0.14%	0.18%	0.21%
Income Tax+	0	0	0	730K	9.5M	-300.6M	11.8M	59.4M	82.4M	144.7M
Effective Tax Rate %	1%	1%	1%	0.97%	0.8%	3.82%	0.88%	0.72%	0.75%	0.7%
Net Income+	-88.93M	-141.09M	-142.54M	21.11M	37M	407.3M	89.6M	154.5M	249.7M	341.3M
Net Margin %	-4.5%	-9.41%	-0.88%	0.05%	0.05%	0.39%	0.08%	0.1%	0.13%	0.14%
Net Income Growth %	-0.47%	-0.59%	-0.01%	1.15%	0.75%	10.01%	-0.78%	0.72%	0.62%	0.37%
Net Income (Continuing)	-88.93M	-141.09M	-142.54M	21.11M	37M	407.3M	89.6M	154.5M	249.7M	341.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.05	-1.63	-1.62	0.22	0.39	4.16	0.92	1.56	2.47	3.29
EPS Growth %	-0.3%	-0.55%	0.01%	1.14%	0.77%	9.67%	-0.78%	0.7%	0.58%	0.33%
EPS (Basic)	-1.05	-1.63	-1.62	0.22	0.40	4.37	0.95	1.61	2.56	3.40
Diluted Shares Outstanding	84.5M	86.71M	88.09M	95.4M	95.73M	97.8M	97.9M	98.9M	101M	103.7M
Basic Shares Outstanding	84.5M	86.56M	87.99M	95.4M	91.63M	93.1M	94.6M	95.8M	97.7M	100.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	384.07M	310.44M	554.92M	737.78M	831M	1.02B	972.8M	1.45B	1.61B	1.72B
Cash & Short-Term Investments	379.19M	307.35M	515.93M	650.91M	670.5M	801M	711.3M	989.3M	1.03B	1.08B
Cash Only	74.19M	83.27M	254.71M	141.71M	112.3M	187.1M	340.8M	262.9M	251.1M	233M
Short-Term Investments	305M	224.08M	261.22M	509.2M	558.2M	613.9M	370.5M	726.4M	780.5M	843.1M
Accounts Receivable	0	0	31.13M	57.41M	126.6M	157.1M	185.5M	350M	439.3M	479.1M
Days Sales Outstanding	-	-	70.29	46.44	58.63	54.83	59.73	85.81	84.97	74.25
Inventory	0	0	1.02M	10.86M	17.3M	28M	30.5M	35.1M	38.3M	57.4M
Days Inventory Outstanding	-	-	298.05	809.26	853.31	1.01K	778.5	552.22	352.13	616.21
Other Current Assets	4.88M	3.09M	6.84M	18.59M	16.6M	30.1M	45.5M	79.1M	97.8M	112.1M
Total Non-Current Assets+	90.71M	54.64M	262.67M	255.37M	475M	718.5M	1.1B	915.2M	1.64B	1.99B
Property, Plant & Equipment	3.43M	6.27M	10.81M	33.87M	116.2M	127.4M	155.8M	145.6M	347.3M	592M
Fixed Asset Turnover	5.76x	2.39x	14.95x	13.32x	6.78x	8.21x	7.28x	10.22x	5.43x	3.98x
Goodwill	0	0	0	0	0	0	0	0	0	5.7M
Intangible Assets	0	0	0	0	0	0	0	37.2M	35.5M	36.5M
Long-Term Investments	82.49M	43.49M	247.36M	216.03M	355.6M	265.3M	624.4M	401.5M	849.4M	864.3M
Other Non-Current Assets	4.79M	4.88M	4.5M	5.48M	3.2M	6.4M	4.4M	25M	49.6M	9.8M
Total Assets+	474.79M	365.09M	817.59M	993.15M	1.31B	1.73B	2.07B	2.37B	3.25B	3.72B
Asset Turnover	0.04x	0.04x	0.20x	0.45x	0.60x	0.60x	0.55x	0.63x	0.58x	0.63x
Asset Growth %	0.95%	-0.23%	1.24%	0.21%	0.32%	0.33%	0.19%	0.14%	0.37%	0.14%
Total Current Liabilities+	25.71M	30.41M	54.43M	88.23M	565.3M	186.5M	245.8M	537.7M	654.8M	507.7M
Accounts Payable	2.56M	5.08M	5.65M	38.38M	41.4M	39.4M	51.5M	67.3M	133.3M	110M
Days Payables Outstanding	-	-	1.64K	2.86K	2.04K	1.42K	1.31K	1.06K	1.23K	1.18K
Short-Term Debt	0	0	0	0	408.8M	0	0	169.4M	170.1M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	11.48M	13.79M	25.81M	42.78M	84.7M	90.6M	133.3M	225.4M	261.4M	297.7M
Current Ratio	14.94x	10.21x	10.20x	8.36x	1.47x	5.45x	3.96x	2.70x	2.45x	3.40x
Quick Ratio	14.94x	10.21x	10.18x	8.24x	1.44x	5.30x	3.83x	2.64x	2.40x	3.28x
Cash Conversion Cycle	-	-	-1.28K	-2K	-1.13K	-357.16	-476.28	-420.78	-788.46	-490.43
Total Non-Current Liabilities+	24.62M	19.8M	391.03M	424.15M	103.8M	422M	452.7M	123.2M	364.6M	621.3M
Long-Term Debt	0	0	369.62M	388.5M	0	317.9M	335.1M	0	0	0
Capital Lease Obligations	0	0	0	0	86.7M	94.4M	105.3M	93.5M	258.3M	455.1M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	14.38M	9.56M	11.18M	25.43M	17.1M	9.7M	12.3M	29.7M	106.3M	166.2M
Total Liabilities	50.33M	50.21M	445.45M	512.39M	669.1M	608.5M	698.5M	660.9M	1.02B	1.13B
Total Debt+	0	0	369.62M	388.5M	495.5M	412.3M	440.4M	262.9M	428.4M	455.1M
Net Debt	-74.19M	-83.27M	114.91M	246.78M	383.2M	225.2M	99.6M	0	177.3M	222.1M
Debt / Equity	-	-	0.99x	0.81x	0.78x	0.37x	0.32x	0.15x	0.19x	0.18x
Debt / EBITDA	-	-	-	9.52x	6.21x	2.40x	3.88x	0.99x	1.57x	0.76x
Net Debt / EBITDA	-	-	-	6.05x	4.80x	1.31x	0.88x	-	0.65x	0.37x
Interest Coverage	-	-	-6.73x	1.21x	2.26x	4.97x	3.97x	35.07x	54.54x	4.51x
Total Equity+	424.45M	314.88M	372.14M	480.76M	636.9M	1.13B	1.37B	1.71B	2.23B	2.59B
Equity Growth %	1.03%	-0.26%	0.18%	0.29%	0.32%	0.77%	0.22%	0.24%	0.31%	0.16%
Book Value per Share	5.02	3.63	4.22	5.04	6.65	11.52	14.03	17.27	22.10	24.97
Total Shareholders' Equity	424.45M	314.88M	372.14M	480.76M	636.9M	1.13B	1.37B	1.71B	2.23B	2.59B
Common Stock	86K	87K	89K	91K	92K	100K	100K	100K	100K	100K
Retained Earnings	-915.23M	-1.06B	-1.2B	-1.18B	-1.13B	-725.4M	-635.8M	-406.8M	-157.1M	29.2M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-977K	-318K	-1.85M	-1.93M	1.4M	1.8M	-1.7M	-7.9M	7M	5.8M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-38M	-106.18M	-94.33M	101.4M	147M	228.5M	256.5M	339.4M	389.9M	595.4M
Operating CF Margin %	-1.92%	-7.08%	-0.58%	0.22%	0.19%	0.22%	0.23%	0.23%	0.21%	0.25%
Operating CF Growth %	0.19%	-1.79%	0.11%	2.07%	0.45%	0.55%	0.12%	0.32%	0.15%	0.53%
Net Income	-88.93M	-141.09M	-142.54M	21.1M	37M	407.3M	89.6M	154.5M	249.7M	341.3M
Depreciation & Amortization	1.01M	1.45M	2.4M	4M	7.4M	8.6M	10.9M	15.6M	21.3M	27.1M
Stock-Based Compensation	28.39M	28.46M	42.52M	58.1M	75.3M	100M	134.2M	173.1M	194.3M	195.5M
Deferred Taxes	0	0	0	0	0	-310.7M	4.3M	19.1M	-56.7M	-123.1M
Other Non-Cash Items	12.83M	-789K	12.1M	19.9M	32.1M	61.2M	800K	44.5M	-46.9M	173.8M
Working Capital Changes	8.7M	5.78M	-8.81M	-1.7M	-4.8M	-37.9M	16.7M	-67.4M	28.2M	-19.2M
Change in Receivables	0	0	-31.13M	-25.1M	-69.2M	-30.5M	-28.4M	-162.2M	-89.3M	-39.8M
Change in Inventory	0	0	-1.02M	-3.5M	-6.4M	-10.7M	-2.5M	-2.6M	5.4M	-19.1M
Change in Payables	9.84M	4.4M	27.34M	0	0	26.9M	56.8M	114.6M	64.3M	29M
Cash from Investing+	-195.81M	112.95M	-251.25M	-242.9M	-211.1M	4.1M	-130.2M	-177.1M	-467.1M	-126.8M
Capital Expenditures	-1.93M	-4.11M	-6.94M	-24.8M	-14.7M	-10.9M	-23.4M	-16.5M	-28.3M	-38.2M
CapEx % of Revenue	0.1%	0.27%	0.04%	0.05%	0.02%	0.01%	0.02%	0.01%	0.01%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	49K	13K	7K	0	0	0	0	0	0	0
Cash from Financing+	276.99M	2.39M	516.65M	29.5M	32.4M	-157.8M	27.4M	-234.3M	65.3M	-486.7M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	-30K	5.09M	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-39.93M	-110.29M	-101.27M	76.6M	132.3M	217.6M	233.1M	322.9M	361.6M	557.2M
FCF Margin %	-2.02%	-7.35%	-0.63%	0.17%	0.17%	0.21%	0.21%	0.22%	0.19%	0.24%
FCF Growth %	0.18%	-1.76%	0.08%	1.76%	0.73%	0.64%	0.07%	0.39%	0.12%	0.54%
FCF per Share	-0.47	-1.27	-1.15	0.80	1.38	2.22	2.38	3.26	3.58	5.37
FCF Conversion (FCF/Net Income)	0.43x	0.75x	0.66x	4.80x	3.97x	0.56x	2.86x	2.20x	1.56x	1.74x
Interest Paid	0	0	0	0	11.6M	11.6M	8.6M	6.6M	3.8M	1.6M
Taxes Paid	0	0	0	0	500K	15.3M	5.1M	14.4M	51.5M	217.5M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-28.09%	-38.17%	-41.5%	4.95%	6.62%	46.2%	7.17%	10.03%	12.68%	14.16%
Return on Invested Capital (ROIC)	-26.76%	-37.99%	-27.42%	4.54%	6.21%	10.31%	5.44%	11.74%	9.14%	16.39%
Gross Margin	100%	100%	99.22%	98.91%	99.06%	99.03%	98.74%	98.44%	97.9%	98.56%
Net Margin	-449.84%	-940.6%	-88.19%	4.68%	4.69%	38.94%	7.9%	10.38%	13.23%	14.49%
Debt / Equity	-	-	0.99x	0.81x	0.78x	0.37x	0.32x	0.15x	0.19x	0.18x
Interest Coverage	-	-	-6.73x	1.21x	2.26x	4.97x	3.97x	35.07x	54.54x	4.51x
FCF Conversion	0.43x	0.75x	0.66x	4.80x	3.97x	0.56x	2.86x	2.20x	1.56x	1.74x
Revenue Growth	-	-24.12%	977.51%	179.16%	74.67%	32.71%	8.38%	31.34%	26.76%	24.81%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	409.61M	752.9M	994.1M	1.09B	1.44B	1.86B	2.33B
Product Growth	-	83.81%	32.04%	9.66%	32.18%	29.13%	25.26%
Collaboration Revenue	41.63M	35.19M	51.8M	43.4M	47.8M	26.5M	24.7M
Collaboration Revenue Growth	-	-15.48%	47.21%	-16.22%	10.14%	-44.56%	-6.79%

Frequently Asked Questions

Valuation & Price

Neurocrine Biosciences, Inc. (NBIX) has a price-to-earnings (P/E) ratio of 40.5x. This suggests investors expect higher future growth.

Growth & Financials

Neurocrine Biosciences, Inc. (NBIX) reported $2.68B in revenue for fiscal year 2024. This represents a 3365% increase from $77.4M in 2011.

Neurocrine Biosciences, Inc. (NBIX) grew revenue by 24.8% over the past year. This is strong growth.

Yes, Neurocrine Biosciences, Inc. (NBIX) is profitable, generating $428.0M in net income for fiscal year 2024 (14.5% net margin).

Dividend & Returns

Neurocrine Biosciences, Inc. (NBIX) has a return on equity (ROE) of 14.2%. This is reasonable for most industries.

Neurocrine Biosciences, Inc. (NBIX) generated $593.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Neurocrine Biosciences, Inc. (NBIX) 10-Year Financial Performance & Capital Metrics

NBIX • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsCNS & Pain Management

Revenue $2.36B +24.8%
EBITDA $598M +119.5%
Net Income $341M +36.7%
EPS (Diluted) 3.29 +33.2%
Gross Margin 98.56% +0.7%
EBITDA Margin 25.37% +75.9%
Operating Margin 24.22% +82.2%
Net Margin 14.49% +9.5%
ROE 14.16% +11.7%
ROIC 16.39% +79.3%
Debt/Equity 0.18 -8.4%
Interest Coverage 4.51 -91.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y profit CAGR of 56.0%
✓Strong Piotroski F-Score: 8/9
✓FCF machine: 23.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 24.5%
✓Healthy 5Y average net margin of 17.0%

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y24.48%

3Y27.61%

TTM19.61%

Profit (Net Income) CAGR

10Y-

5Y55.95%

3Y56.17%

TTM10.91%

EPS CAGR

10Y-

5Y53.19%

3Y52.92%

TTM12.06%

ROCE

10Y Avg-1.13%

5Y Avg12.98%

3Y Avg14.87%

Latest19.65%

Peer Comparison

CNS & Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NBIXNeurocrine Biosciences, Inc.	13.3B	133.35	40.53	24.81%	15.95%	14.25%	4.19%	0.18
SUPNSupernus Pharmaceuticals, Inc.	2.88B	50.26	38.08	8.94%	-2.8%	-1.82%	5.94%	0.03
PTPIPetros Pharmaceuticals, Inc.	338.98K	0.01	-0.00	-12.2%	-9.68%	-208.53%
QNTMQuantum BioPharma Ltd.	26.75M	6.96	-0.56			-379.78%		0.08
AYTUAytu BioPharma, Inc.	28.12M	2.76	-1.28	1.84%	-20.52%	-56.41%		1.21
AQSTAquestive Therapeutics, Inc.	407.49M	3.34	-6.55	13.8%	-158.95%
AVDLAvadel Pharmaceuticals plc	2.11B	21.48	-42.12	5.05%	-0.11%	-0.28%		0.02
RGCRegencell Bioscience Holdings Limited	14.86B	30.06	-3455.17			-67.02%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	19.77M	15M	161.63M	451.2M	788.1M	1.05B	1.13B	1.49B	1.89B	2.36B
Revenue Growth %	-	-0.24%	9.78%	1.79%	0.75%	0.33%	0.08%	0.31%	0.27%	0.25%
Cost of Goods Sold+	0	0	1.25M	4.9M	7.4M	10.1M	14.3M	23.2M	39.7M	34M
COGS % of Revenue	-	-	0.01%	0.01%	0.01%	0.01%	0.01%	0.02%	0.02%	0.01%
Gross Profit+	19.77M	15M	160.37M	446.3M	780.7M	1.04B	1.12B	1.47B	1.85B	2.32B
Gross Margin %	1%	1%	0.99%	0.99%	0.99%	0.99%	0.99%	0.98%	0.98%	0.99%
Gross Profit Growth %	2.37%	-0.24%	9.69%	1.78%	0.75%	0.33%	0.08%	0.31%	0.26%	0.26%
Operating Expenses+	113.97M	162.37M	291.73M	409.5M	708.4M	872.8M	1.02B	1.22B	1.6B	1.75B
OpEx % of Revenue	5.77%	10.82%	1.8%	0.91%	0.9%	0.83%	0.9%	0.82%	0.85%	0.74%
Selling, General & Admin	32.48M	68.08M	169.91M	248.93M	354.1M	433.3M	583.3M	752.7M	887.6M	1.01B
SG&A % of Revenue	1.64%	4.54%	1.05%	0.55%	0.45%	0.41%	0.51%	0.51%	0.47%	0.43%
Research & Development	81.49M	94.29M	91.83M	155.8M	200M	275M	328.1M	463.8M	565M	731.1M
R&D % of Revenue	4.12%	6.29%	0.57%	0.35%	0.25%	0.26%	0.29%	0.31%	0.3%	0.31%
Other Operating Expenses	0	0	30M	4.8M	154.3M	164.5M	105.3M	0	143.9M	12.5M
Operating Income+	-94.2M	-147.37M	-131.36M	36.8M	72.3M	163M	102.5M	249M	250.9M	570.5M
Operating Margin %	-4.77%	-9.82%	-0.81%	0.08%	0.09%	0.16%	0.09%	0.17%	0.13%	0.24%
Operating Income Growth %	-0.46%	-0.56%	0.11%	1.28%	0.96%	1.25%	-0.37%	1.43%	0.01%	1.27%
EBITDA+	-93.19M	-145.87M	-128.96M	40.82M	79.75M	171.6M	113.4M	264.6M	272.2M	597.6M
EBITDA Margin %	-4.71%	-9.72%	-0.8%	0.09%	0.1%	0.16%	0.1%	0.18%	0.14%	0.25%
EBITDA Growth %	-0.47%	-0.57%	0.12%	1.32%	0.95%	1.15%	-0.34%	1.33%	0.03%	1.2%
D&A (Non-Cash Add-back)	1.01M	1.5M	2.4M	4.02M	7.45M	8.6M	10.9M	15.6M	21.3M	27.1M
EBIT	-88.93M	-141.09M	-123.02M	52.3M	78.5M	139.5M	127.2M	249M	394.8M	612.6M
Net Interest Income+	1.93M	2.84M	-19.52M	-30.5M	-32M	-32.8M	-25.8M	4.1M	-4.6M	-35.6M
Interest Income	1.93M	2.84M	0	0	0	0	0	11.2M	0	91M
Interest Expense	0	0	19.52M	30.53M	32M	32.8M	25.8M	7.1M	4.6M	126.6M
Other Income/Expense	5.27M	6.28M	-11.18M	-15.05M	-25.8M	-56.3M	-1.1M	-35.1M	81.2M	-84.5M
Pretax Income+	-88.93M	-141.09M	-142.54M	21.84M	46.5M	106.7M	101.4M	213.9M	332.1M	486M
Pretax Margin %	-4.5%	-9.41%	-0.88%	0.05%	0.06%	0.1%	0.09%	0.14%	0.18%	0.21%
Income Tax+	0	0	0	730K	9.5M	-300.6M	11.8M	59.4M	82.4M	144.7M
Effective Tax Rate %	1%	1%	1%	0.97%	0.8%	3.82%	0.88%	0.72%	0.75%	0.7%
Net Income+	-88.93M	-141.09M	-142.54M	21.11M	37M	407.3M	89.6M	154.5M	249.7M	341.3M
Net Margin %	-4.5%	-9.41%	-0.88%	0.05%	0.05%	0.39%	0.08%	0.1%	0.13%	0.14%
Net Income Growth %	-0.47%	-0.59%	-0.01%	1.15%	0.75%	10.01%	-0.78%	0.72%	0.62%	0.37%
Net Income (Continuing)	-88.93M	-141.09M	-142.54M	21.11M	37M	407.3M	89.6M	154.5M	249.7M	341.3M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.05	-1.63	-1.62	0.22	0.39	4.16	0.92	1.56	2.47	3.29
EPS Growth %	-0.3%	-0.55%	0.01%	1.14%	0.77%	9.67%	-0.78%	0.7%	0.58%	0.33%
EPS (Basic)	-1.05	-1.63	-1.62	0.22	0.40	4.37	0.95	1.61	2.56	3.40
Diluted Shares Outstanding	84.5M	86.71M	88.09M	95.4M	95.73M	97.8M	97.9M	98.9M	101M	103.7M
Basic Shares Outstanding	84.5M	86.56M	87.99M	95.4M	91.63M	93.1M	94.6M	95.8M	97.7M	100.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	384.07M	310.44M	554.92M	737.78M	831M	1.02B	972.8M	1.45B	1.61B	1.72B
Cash & Short-Term Investments	379.19M	307.35M	515.93M	650.91M	670.5M	801M	711.3M	989.3M	1.03B	1.08B
Cash Only	74.19M	83.27M	254.71M	141.71M	112.3M	187.1M	340.8M	262.9M	251.1M	233M
Short-Term Investments	305M	224.08M	261.22M	509.2M	558.2M	613.9M	370.5M	726.4M	780.5M	843.1M
Accounts Receivable	0	0	31.13M	57.41M	126.6M	157.1M	185.5M	350M	439.3M	479.1M
Days Sales Outstanding	-	-	70.29	46.44	58.63	54.83	59.73	85.81	84.97	74.25
Inventory	0	0	1.02M	10.86M	17.3M	28M	30.5M	35.1M	38.3M	57.4M
Days Inventory Outstanding	-	-	298.05	809.26	853.31	1.01K	778.5	552.22	352.13	616.21
Other Current Assets	4.88M	3.09M	6.84M	18.59M	16.6M	30.1M	45.5M	79.1M	97.8M	112.1M
Total Non-Current Assets+	90.71M	54.64M	262.67M	255.37M	475M	718.5M	1.1B	915.2M	1.64B	1.99B
Property, Plant & Equipment	3.43M	6.27M	10.81M	33.87M	116.2M	127.4M	155.8M	145.6M	347.3M	592M
Fixed Asset Turnover	5.76x	2.39x	14.95x	13.32x	6.78x	8.21x	7.28x	10.22x	5.43x	3.98x
Goodwill	0	0	0	0	0	0	0	0	0	5.7M
Intangible Assets	0	0	0	0	0	0	0	37.2M	35.5M	36.5M
Long-Term Investments	82.49M	43.49M	247.36M	216.03M	355.6M	265.3M	624.4M	401.5M	849.4M	864.3M
Other Non-Current Assets	4.79M	4.88M	4.5M	5.48M	3.2M	6.4M	4.4M	25M	49.6M	9.8M
Total Assets+	474.79M	365.09M	817.59M	993.15M	1.31B	1.73B	2.07B	2.37B	3.25B	3.72B
Asset Turnover	0.04x	0.04x	0.20x	0.45x	0.60x	0.60x	0.55x	0.63x	0.58x	0.63x
Asset Growth %	0.95%	-0.23%	1.24%	0.21%	0.32%	0.33%	0.19%	0.14%	0.37%	0.14%
Total Current Liabilities+	25.71M	30.41M	54.43M	88.23M	565.3M	186.5M	245.8M	537.7M	654.8M	507.7M
Accounts Payable	2.56M	5.08M	5.65M	38.38M	41.4M	39.4M	51.5M	67.3M	133.3M	110M
Days Payables Outstanding	-	-	1.64K	2.86K	2.04K	1.42K	1.31K	1.06K	1.23K	1.18K
Short-Term Debt	0	0	0	0	408.8M	0	0	169.4M	170.1M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	11.48M	13.79M	25.81M	42.78M	84.7M	90.6M	133.3M	225.4M	261.4M	297.7M
Current Ratio	14.94x	10.21x	10.20x	8.36x	1.47x	5.45x	3.96x	2.70x	2.45x	3.40x
Quick Ratio	14.94x	10.21x	10.18x	8.24x	1.44x	5.30x	3.83x	2.64x	2.40x	3.28x
Cash Conversion Cycle	-	-	-1.28K	-2K	-1.13K	-357.16	-476.28	-420.78	-788.46	-490.43
Total Non-Current Liabilities+	24.62M	19.8M	391.03M	424.15M	103.8M	422M	452.7M	123.2M	364.6M	621.3M
Long-Term Debt	0	0	369.62M	388.5M	0	317.9M	335.1M	0	0	0
Capital Lease Obligations	0	0	0	0	86.7M	94.4M	105.3M	93.5M	258.3M	455.1M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	14.38M	9.56M	11.18M	25.43M	17.1M	9.7M	12.3M	29.7M	106.3M	166.2M
Total Liabilities	50.33M	50.21M	445.45M	512.39M	669.1M	608.5M	698.5M	660.9M	1.02B	1.13B
Total Debt+	0	0	369.62M	388.5M	495.5M	412.3M	440.4M	262.9M	428.4M	455.1M
Net Debt	-74.19M	-83.27M	114.91M	246.78M	383.2M	225.2M	99.6M	0	177.3M	222.1M
Debt / Equity	-	-	0.99x	0.81x	0.78x	0.37x	0.32x	0.15x	0.19x	0.18x
Debt / EBITDA	-	-	-	9.52x	6.21x	2.40x	3.88x	0.99x	1.57x	0.76x
Net Debt / EBITDA	-	-	-	6.05x	4.80x	1.31x	0.88x	-	0.65x	0.37x
Interest Coverage	-	-	-6.73x	1.21x	2.26x	4.97x	3.97x	35.07x	54.54x	4.51x
Total Equity+	424.45M	314.88M	372.14M	480.76M	636.9M	1.13B	1.37B	1.71B	2.23B	2.59B
Equity Growth %	1.03%	-0.26%	0.18%	0.29%	0.32%	0.77%	0.22%	0.24%	0.31%	0.16%
Book Value per Share	5.02	3.63	4.22	5.04	6.65	11.52	14.03	17.27	22.10	24.97
Total Shareholders' Equity	424.45M	314.88M	372.14M	480.76M	636.9M	1.13B	1.37B	1.71B	2.23B	2.59B
Common Stock	86K	87K	89K	91K	92K	100K	100K	100K	100K	100K
Retained Earnings	-915.23M	-1.06B	-1.2B	-1.18B	-1.13B	-725.4M	-635.8M	-406.8M	-157.1M	29.2M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-977K	-318K	-1.85M	-1.93M	1.4M	1.8M	-1.7M	-7.9M	7M	5.8M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-38M	-106.18M	-94.33M	101.4M	147M	228.5M	256.5M	339.4M	389.9M	595.4M
Operating CF Margin %	-1.92%	-7.08%	-0.58%	0.22%	0.19%	0.22%	0.23%	0.23%	0.21%	0.25%
Operating CF Growth %	0.19%	-1.79%	0.11%	2.07%	0.45%	0.55%	0.12%	0.32%	0.15%	0.53%
Net Income	-88.93M	-141.09M	-142.54M	21.1M	37M	407.3M	89.6M	154.5M	249.7M	341.3M
Depreciation & Amortization	1.01M	1.45M	2.4M	4M	7.4M	8.6M	10.9M	15.6M	21.3M	27.1M
Stock-Based Compensation	28.39M	28.46M	42.52M	58.1M	75.3M	100M	134.2M	173.1M	194.3M	195.5M
Deferred Taxes	0	0	0	0	0	-310.7M	4.3M	19.1M	-56.7M	-123.1M
Other Non-Cash Items	12.83M	-789K	12.1M	19.9M	32.1M	61.2M	800K	44.5M	-46.9M	173.8M
Working Capital Changes	8.7M	5.78M	-8.81M	-1.7M	-4.8M	-37.9M	16.7M	-67.4M	28.2M	-19.2M
Change in Receivables	0	0	-31.13M	-25.1M	-69.2M	-30.5M	-28.4M	-162.2M	-89.3M	-39.8M
Change in Inventory	0	0	-1.02M	-3.5M	-6.4M	-10.7M	-2.5M	-2.6M	5.4M	-19.1M
Change in Payables	9.84M	4.4M	27.34M	0	0	26.9M	56.8M	114.6M	64.3M	29M
Cash from Investing+	-195.81M	112.95M	-251.25M	-242.9M	-211.1M	4.1M	-130.2M	-177.1M	-467.1M	-126.8M
Capital Expenditures	-1.93M	-4.11M	-6.94M	-24.8M	-14.7M	-10.9M	-23.4M	-16.5M	-28.3M	-38.2M
CapEx % of Revenue	0.1%	0.27%	0.04%	0.05%	0.02%	0.01%	0.02%	0.01%	0.01%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	49K	13K	7K	0	0	0	0	0	0	0
Cash from Financing+	276.99M	2.39M	516.65M	29.5M	32.4M	-157.8M	27.4M	-234.3M	65.3M	-486.7M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	-30K	5.09M	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-39.93M	-110.29M	-101.27M	76.6M	132.3M	217.6M	233.1M	322.9M	361.6M	557.2M
FCF Margin %	-2.02%	-7.35%	-0.63%	0.17%	0.17%	0.21%	0.21%	0.22%	0.19%	0.24%
FCF Growth %	0.18%	-1.76%	0.08%	1.76%	0.73%	0.64%	0.07%	0.39%	0.12%	0.54%
FCF per Share	-0.47	-1.27	-1.15	0.80	1.38	2.22	2.38	3.26	3.58	5.37
FCF Conversion (FCF/Net Income)	0.43x	0.75x	0.66x	4.80x	3.97x	0.56x	2.86x	2.20x	1.56x	1.74x
Interest Paid	0	0	0	0	11.6M	11.6M	8.6M	6.6M	3.8M	1.6M
Taxes Paid	0	0	0	0	500K	15.3M	5.1M	14.4M	51.5M	217.5M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-28.09%	-38.17%	-41.5%	4.95%	6.62%	46.2%	7.17%	10.03%	12.68%	14.16%
Return on Invested Capital (ROIC)	-26.76%	-37.99%	-27.42%	4.54%	6.21%	10.31%	5.44%	11.74%	9.14%	16.39%
Gross Margin	100%	100%	99.22%	98.91%	99.06%	99.03%	98.74%	98.44%	97.9%	98.56%
Net Margin	-449.84%	-940.6%	-88.19%	4.68%	4.69%	38.94%	7.9%	10.38%	13.23%	14.49%
Debt / Equity	-	-	0.99x	0.81x	0.78x	0.37x	0.32x	0.15x	0.19x	0.18x
Interest Coverage	-	-	-6.73x	1.21x	2.26x	4.97x	3.97x	35.07x	54.54x	4.51x
FCF Conversion	0.43x	0.75x	0.66x	4.80x	3.97x	0.56x	2.86x	2.20x	1.56x	1.74x
Revenue Growth	-	-24.12%	977.51%	179.16%	74.67%	32.71%	8.38%	31.34%	26.76%	24.81%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Product	409.61M	752.9M	994.1M	1.09B	1.44B	1.86B	2.33B
Product Growth	-	83.81%	32.04%	9.66%	32.18%	29.13%	25.26%
Collaboration Revenue	41.63M	35.19M	51.8M	43.4M	47.8M	26.5M	24.7M
Collaboration Revenue Growth	-	-15.48%	47.21%	-16.22%	10.14%	-44.56%	-6.79%

Frequently Asked Questions

Valuation & Price

Neurocrine Biosciences, Inc. (NBIX) has a price-to-earnings (P/E) ratio of 40.5x. This suggests investors expect higher future growth.

Growth & Financials

Neurocrine Biosciences, Inc. (NBIX) reported $2.68B in revenue for fiscal year 2024. This represents a 3365% increase from $77.4M in 2011.

Neurocrine Biosciences, Inc. (NBIX) grew revenue by 24.8% over the past year. This is strong growth.

Yes, Neurocrine Biosciences, Inc. (NBIX) is profitable, generating $428.0M in net income for fiscal year 2024 (14.5% net margin).

Dividend & Returns

Neurocrine Biosciences, Inc. (NBIX) has a return on equity (ROE) of 14.2%. This is reasonable for most industries.

Neurocrine Biosciences, Inc. (NBIX) generated $593.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.